Patents Assigned to Talengen International Limited
-
Patent number: 11938172Abstract: The present invention discloses the use of plasminogen to regulate GLP-1/GLP-1R and treat a GLP-1/GLP-1R-related condition.Type: GrantFiled: June 19, 2018Date of Patent: March 26, 2024Assignee: Talengen International LimitedInventor: Jinan Li
-
Publication number: 20240000903Abstract: The present invention relates to a method for promoting the formation of mature BDNF and increasing the level of BDNF. The method comprises administering a therapeutically effective amount of a plasminogen pathway activator to a subject. The present invention also relates to a pharmaceutical composition, a product and a kit which comprises the plasminogen pathway activator and are used for promoting the formation of mature BDNF and increasing the BDNF level.Type: ApplicationFiled: November 17, 2021Publication date: January 4, 2024Applicant: Talengen International LimitedInventor: Jinan LI
-
Publication number: 20240000904Abstract: The present invention relates to a method for promoting the formation of mature NGF and increasing the expression of NGF. The method comprises administering a therapeutically effective amount of a plasminogen pathway activator to a subject. The present invention further relates to a pharmaceutical composition, a product and a kit comprising the plasminogen pathway activator for promoting the formation of mature NGF and increasing the expression of NGF.Type: ApplicationFiled: November 17, 2021Publication date: January 4, 2024Applicant: Talengen International LimitedInventor: Jinan LI
-
Publication number: 20230346897Abstract: Provided in the present invention is a method for promoting the degradation of a misfolded protein and an aggregate thereof. The method includes administrating a therapeutically effective amount of plasminogen activation pathway components to a subject. Further provided in the present invention are a drug containing the plasminogen activation pathway components, a pharmaceutical composition, a product and a kit, which are used to prevent and treat diseases caused by the misfolded protein and/or the aggregate thereof.Type: ApplicationFiled: March 24, 2021Publication date: November 2, 2023Applicant: Talengen International LimitedInventor: Jinan LI
-
Publication number: 20230302102Abstract: The present invention provides a method for treating a tumor in a subject, maintaining or improving body organ function under tumor conditions, and prolonging the survival period of the subject, comprising administering to the subject a prophylactically and/or therapeutically effective amount of components such as plasminogen of a plasminogen activation pathway. The present invention also provides a medicament comprising plasminogen, a pharmaceutical composition, a formulation and a kit for treating a tumor in a subject.Type: ApplicationFiled: August 20, 2021Publication date: September 28, 2023Applicant: Talengen International LimitedInventor: Jinan LI
-
Publication number: 20230190891Abstract: The present application relates to a method for treating spinal muscular atrophy (SMA), comprising: administering a therapeutically effective amount of a plasminogen pathway activator to a subject. The present application also relates to a pharmaceutical composition, product, and kit comprising said plasminogen pathway activator, which are used for treating spinal muscular atrophy.Type: ApplicationFiled: May 11, 2021Publication date: June 22, 2023Applicant: Talengen International LimitedInventor: Jinan LI
-
Publication number: 20230181699Abstract: Provided is a method for treating spinal muscular atrophy (SMA), comprising: administrating a therapeutically effective amount of a plasminogen pathway activator to a subject. Further provided are a pharmaceutical composition, product and kit comprising said plasminogen pathway activator, which are used for treating spinal muscular atrophy.Type: ApplicationFiled: November 17, 2020Publication date: June 15, 2023Applicant: Talengen International LimitedInventor: Jinan LI
-
Publication number: 20230173039Abstract: The present invention provides a method and drug for preventing and treating Alzheimer disease. The method includes: administering a therapeutically effective amount of a component of a plasminogen activation pathway to a subject. The present invention also provides a drug, pharmaceutical composition, product, and kit containing the component of the plasminogen activation pathway.Type: ApplicationFiled: March 24, 2021Publication date: June 8, 2023Applicant: Talengen International LimitedInventor: Jinan LI
-
Publication number: 20230143354Abstract: Provided is a method for preventing and treating Parkinson's disease, including administering to a subject a therapeutically effective amount of a component of a plasminogen activation pathway. The present invention relates to a drug, a pharmaceutical composition, a product and a kit which include the component of the plasminogen activation pathway for treating the described condition.Type: ApplicationFiled: March 24, 2021Publication date: May 11, 2023Applicant: Talengen International LimitedInventor: Jinan LI
-
Publication number: 20230141921Abstract: Provided are a method and drug for treating Huntington's disease, which includes: administering a therapeutically effective amount of a component of a plasminogen activation pathway or a related compound thereof to a subject. Also provided are a drug, pharmaceutical composition, product, and kit used for treating Huntington's disease and containing the above component or compound.Type: ApplicationFiled: March 24, 2021Publication date: May 11, 2023Applicant: Talengen International LimitedInventor: Jinan LI
-
Patent number: 11642397Abstract: The present invention relates to a method and a drug for preventing or treating osteoarthritis by plasminogen. Specifically, the present invention involves administering an effective amount of plasminogen to an osteoarthritis subject for treating the osteoarthritis. In addition, the present invention further relates to an osteoarthritis treatment drug comprising plasminogen, a product, and a kit.Type: GrantFiled: December 17, 2018Date of Patent: May 9, 2023Assignee: TALENGEN INTERNATIONAL LIMITEDInventor: Jinan Li
-
Publication number: 20230139956Abstract: The present application relates to a method for treating abnormal blood pressure condition, which comprises: administrating an effective amount of a component of plasminogen activation pathway to a subject. The present application also relates to a medicament and a product for treating an abnormal blood pressure condition, and use thereof.Type: ApplicationFiled: February 26, 2021Publication date: May 4, 2023Applicant: Talengen International LimitedInventor: Jinan LI
-
Publication number: 20230081922Abstract: Provided is a method for treating viral pneumonia, comprising: administrating a therapeutically effective amount of a component of plasminogen activation pathway to a subject. Also provided are a medicament, a pharmaceutical composition, a product, and a kit which comprise a component of plasminogen activation pathway for treating viral pneumonia.Type: ApplicationFiled: February 8, 2021Publication date: March 16, 2023Applicant: Talengen International LimitedInventor: Jinan LI
-
Publication number: 20230084586Abstract: Provided is a method for preventing and treating multiple sclerosis, comprising administering a therapeutically effective amount of a component of plasminogen activation pathway to a subject. Also provided are a medicament, a pharmaceutical composition, a product, and a kit which comprise a component of plasminogen activation pathway for treating said disease.Type: ApplicationFiled: February 8, 2021Publication date: March 16, 2023Applicant: Talengen International LimitedInventor: Jinan LI
-
Publication number: 20230066726Abstract: Provided is a method for treatment of nerve injury and a related disease, comprising: administrating a therapeutically effective amount of a component of plasminogen activation pathway to a subject. Also provided are a medicament, a pharmaceutical composition, a product, and a kit which comprise a component of plasminogen activation pathway for treating the above diseases.Type: ApplicationFiled: January 18, 2021Publication date: March 2, 2023Applicant: Talengen International LimitedInventor: Jinan LI
-
Patent number: 11547746Abstract: The present invention relates to a method for preventing and/or treating coronary atherosclerosis and its related conditions in a subject, comprising administering a prophylactically and/or therapeutically effective amount of plasminogen to the subject, wherein the subject suffers from, is suspected of suffering from coronary atherosclerosis and its related conditions, or has a risk of suffering from coronary atherosclerosis and its related conditions. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating coronary atherosclerosis and its related conditions in a subject.Type: GrantFiled: June 19, 2017Date of Patent: January 10, 2023Assignee: Talengen International LimitedInventor: Jinan Li
-
Patent number: 11478535Abstract: The present invention relates to a method for preventing and/or treating fatty liver and its related conditions in a subject, comprising administering an effective amount of plasminogen to the subject; in another aspect, the present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating fatty liver and its related conditions in the subject.Type: GrantFiled: June 19, 2017Date of Patent: October 25, 2022Assignee: Talengen International LimitedInventor: Jinan Li
-
Patent number: 11400142Abstract: The present invention relates to the use of plasminogen in the prevention and/or treatment of diabetic neuropathic pain and neurohypersensitivity, and in the repair of nerve tissue injury. Therefore, plasminogen may become a new strategy for preventing and treating diabetic neuropathic pain.Type: GrantFiled: December 16, 2016Date of Patent: August 2, 2022Assignee: Talengen International LimitedInventor: Jinan Li
-
Patent number: 11389515Abstract: The present invention relates to a method for preventing and/or treating hyperlipemia and its related conditions in a subject, comprising administering a prophylactically and/or therapeutically effective amount of plasminogen to the subject susceptible to hyperlipemia, suffers from hyperlipemia or other diseases accompanied by hyperlipemia. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating hyperlipemia and its related conditions in a subject.Type: GrantFiled: June 19, 2017Date of Patent: July 19, 2022Assignee: Talengen International LimitedInventor: Jinan Li
-
Patent number: 11338022Abstract: The present invention relates to the effect of plasminogen in the treatment and/or elimination of angiocardiopathy, especially angiocardiopathy caused by diabetes mellitus, thereby providing a new strategy for treating different kinds of angiocardiopathy, especially angiocardiopathy and its related disorders caused by diabetes mellitus.Type: GrantFiled: December 16, 2016Date of Patent: May 24, 2022Assignee: TALENGEN INTERNATIONAL LIMITEDInventor: Jinan Li